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IN THIS ISSUE 
ANew Autoantigen in the BMZ 
The basement membrane zone (BMZ) of the skin is a complex 
structure that provides adhesion between the dermis and epidermis. 
It also serves as a barrier to inflammatory and neoplastic cell migra-
tion. Several proteoglycans and fibrous elements including type IV 
collagen make up the matrix of the basal lamina. In addition, the 
dermis contributes substructural components in the form of micro-
fibrillar bundles and anchoring fibrils of type VII collagen. Initial 
identification and characterization of some elements was through 
their involvement as the targets of autoimmune reactions. The au-
toantigens of bullous pemphigoid (BP) and epidermolysis bullosa 
acquisita (EBA) are such proteins. According to Lawrence Chan and 
his co-workers, "Identification of these 'autoantigens' significantly 
improves our understanding of the normal structure of the BMZ, 
and assists the medical community in making precise clinical diag-
noses." In this issue (p. 262) these investigators present a unique 
patient with non-scarring, toxic epidermal necrolysis-like blistering 
disease mediated by IgG antibodies against a component of the 
BMZ. They identify the autoantigen target and characterize the 
clinical profile of a new blistering dermatosis. 
Initial immunologic findings showed a similarity to EBA; IgG 
an~ C3 .deposits were visualized in the BMZ, and circulating IgG 
antl?odles tar~eted the dermal side of salt-split skin preparations. 
U?h~e EBA, I~muno~lectron microscopy localized the deposits 
WIthin the .lamlna luclda and Western immunoblot analysis re-
vealed ~ umque pattern of reactivity. The patient's serum did not 
react .wlth BP or EPA antigens but did identify a 105-kDa protein 
that IS produced and secreted by human keratinocytes and fibro-
blasts. Recently, epiligrin has also been identified as the autoantigen 
in an autoimmune blistering syndrome U Clitl Invest 90:1628-
1633). These newly identified target proteins will allow a fresh look 
at the interrelationship of components in the BMZ. "Clinically," 
Chan states, "this study indicates that precise diagnosis of immune-
mediated subepidermal blistering diseases requires identification of 
the targeted autoantigen at the molecular level." 
On the Relationship Between CD68+ and Epidermal Langerhans Cells . . . 
Dendritic morphology is a visible characteristic of epidermal Lan-
gerhans cells in situ. In addition, these cells are identified by their 
expression of major histocompatibility complex class II antigens, 
CD 1a molecules, ATPases, and Birbeck granules (BG). Langerhans 
cells are derived from the bone marrow and are distributed through 
the blood stream. However, the nature of the circulating precursor 
cell is unknown, as is the rate at which Langerhans cells are re-
placed. It is believed that the precursor is part of the monocytic 
fraction of the blood. CD68 is an early myelomonocyte lineage 
marker that distinguishes the monocyte/macrophage compartment 
of the dermis from the CD1a epidermal Langerhans cells that are 
CD68-. A pilot study designed to investigate the immunopathol-
ogy in pemphigus folliaceous revealed a large population of epider-
mal CD68+ cells. In this issue (p. 256) Petzel bauer and colleagues 
analyze the phenotype of these cells using a panel of monoclonal 
antibodies for antigen identification. They demonstrate that these 
epidermal CD68+ dendritic cells are CD45 and HLA-DR positive 
and, in general, lack CDla expression and BG. However, a small 
portion of these cells coexpresses CD68 and CDla molecules and 
exhibits BG. In contrast, the numbers of classical epidermal Langer-
hans cells are dramatically reduced. Petzel bauer summarizes, 
"These data demonstrate that during the inflammatory process, 
CD68+ cells populating the epidermis from the dermal compart-
ment are replacing the classical epidermal Langerhans cells." He 
feels that "these cells represent Langerhans cell precursors during 
their phenotypic and morphological transformation into resident 
Langerhans cells ." 
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Hormonal Effects of Relaxin on Collagen Organization in the Skin 
Collagen is the major structural protein in the extracellular com-
partment of tissues. It supplies a framework for other matrix ele-
ments and provides the tensile strength of the interstitium. There-
fore, tissue growth and remodeling are highly dependent on the 
regulation of collagen expression. Several growth hormones and 
cytokines affect wound healing in vivo and modulate collagen ex-
pression in vitro. The reproductive hormone, relaxin, occurs natu-
rally in the serum during pregnancy and is thought to playa role in 
'relaxation' of the interpubic ligament and cervix in preparation for 
childbirth. This remodeling is accompanied by disruption of colla-
gen bundle structure. Unemori and her co-workers have examined 
the effects of this hormone on collagen expression in targets outside 
the reproductive system. Previously, they have demonstrated that 
relaxin mediates a decrease in the basal collagen production of nor-
mal dermal fibroblasts, and decreases collagen overproduction in 
cytokine-stimulated cells U Bioi Chern 255:10681-10685, 1990). 
Relaxin also causes a dose-dependent increase in the expression of 
collagenase, producing a general state of collagen disruption. In this 
issue (p. 280) they evaluated the ability of relaxin to modulate colla-
gen accumulation in two rodent models of fibrosis in vivo. Capsule 
formation around implanted osmotic pumps or fibrotic infiltration 
into polyvinyl sponges provided the controlled format for delivery 
of the hormone and measurements of collagen accumulation. Ac-
cording to Unemori, "the results of this study indicate that relaxin is 
effective in causing a dose-related decrease in collagen accumula-
tion" around these implants. Relaxin also can modulate the over-
production of collagen by fibroblasts derived from the skin of pa-
tients with scleroderma (Unemori et aI, ] Invest Dermato! 
99:337 - 342, 1992). Together these studies suggest that "relaxin 
may have utility in modulating the overexpression that is the basis 
of certain diseases." 
Cornifins as a Marker of Squamous Differentiation 
Squamous cell differentiation is a multi-step pathway that occurs in 
many different tissues. It represents normal cellular development in 
the epidermis and esophagus, whereas it is a pathologic condition in 
the lining of the major conducting airways. Although there are 
similarities between these forms of cellular differentiation, the fac-
tors that regulate them and the cellular markers that they express are 
different. The cross-linked envelope (CE) is a characteristic feature 
of advanceq squamous differentiation. It is formed in the stratum 
corneum, just beneath the plasma membrane, by proteins that are 
deposited and covalently crosslinked to each other by the Ca++-de-
pendent type I transglutaminase. Involucrill and loricrin have been 
identified among the CE precursor proteins, as have a recently iden-
tified family of small proline-rich proteins, the cornifins. These 
proteins contain a proline- and glutamine-rich tandem repeat of 
eight amino acids at their carboxy terminus that provides a good 
substrate for crosslinking. 
In this issue (p. 268) Fujimoto et al examine the expression of 
cornifin in several squamous differentiating tissues by immunohis-
tochemistry and in situ hybridization. They demonstrate the pres-
ence of cornifin protein and mRNA in normal epidermis, esophagus 
and tongue, as well as in metaplastic squamous tracheal epithelium 
of vitamin A -deficient hamsters. Parallel studies with probes for 
involucrin and loricrin showed a similar localization of cornifin and 
involucrin. Both were induced in the spinous layer and at an earlier 
stage of development than loricrin. In psoriatic skin, cornifin was 
expressed in larger amounts and in more cell layers. Topical appli-
cation of retinoic acid also resulted in thickening of the skin and an 
enhanced expression of cornifin. This confirms cornifin as a marker 
of squamous differentiation and demonstrates the abnormal regula-
tion of this pathway in psoriasis and retinoic acid-treated skin. 
Prolactin and Keratinocyte Proliferation 
Prolactin (PRL) is a member of the growth hormone family of 
cytokines. It is produced in the anterior pituitary gland and distin-
guished by its ability to stimulate the secretion of milk. It shows 
growth-promoting activity in several target organs, including 
mammary gland, prostate, seminal vesicles, and liver. In addition, 
PRL can stimulate the growth of normal and malignant mammary 
epithelial cells, renal epithelial cells, lymphocytes, thymic epithelial 
cells, and selected pituitary cells. In this issue (p. 275) Girolomoni et 
al extend the list of responsive cell types to include keratinocytes 
grown under defined serum-free conditions. Bovine pituitary ex-
tract (BPE) has long been used to promote the growth of keratino-
cytes in culture. These authors show that the level ofbioactive PRL 
in pituitary extract is in the physiologic range. They further dem-
onstrate that membrane preparations from freshly isolated cells ex-
hibit specific high-affinity PRL binding sites. These observations 
led to a systematic study of the relative importance ofPRL and otner 
hormones as growth-promoting components of pituitary extract. 
PRL alone can substantially replace the growth stimulation by BPE 
in serum-free medium. When epidermal growth factor or hydro-
cortisone was also removed from the medium, PRL stimulated 
growth if insulin was present. 
The receptor for prolactin is also a member of a large gene family 
that includes the receptors for other growth hormones, erythropoi-
etin, interleukins, and granulocyte/macrophage colony-stimulat-
ing factor. Further, according to the authors, "Several molecules 
from diverse sources have been described with extensive sequence 
homology to PRL that have the ability to promote cell prolifera-
tion." PRL-like proteins can bind the PRL receptors and effect 
similar responses in target tissues. Because PRL immunoreactivity 
has been detected in human eccrine sweat glands, the growth stimu-
lus may arise locally. "Ultimately, PRL may be found to be relevant 
in hYl'erproliferative conditions of the eridermis. In this context, 
the effectiveness of Cyclosporine A (CSA) in treating psoriasis cor-
relates with its known capacity to inhibit PRL binding to the PRL 
receptor, suggesting that keratinocytes as well as T lymphocytes 
may be relevant targets of CSA action." This work helps define 
components for serum-free keratinocyte growth medium and pro-
vides a new avenue for studying the physiology and pathology of \' 
keratinocyte proliferation. 
